SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel,...
Hence then, the article about carsgen presents updated long term follow up results for zevor cel at ims 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025 )
Also on site :
- Europe’s cyber agency blames hacking gangs for massive data breach and leak
- The Trump Dictatorship Is Cracking Up
- Ukraine rocked by new multi-million-dollar corruption scandal